Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BRS3 | P32247 | 7/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18106980 | 0.81 | L3MBTL1 (0.54) | HCAR2HCAR3LMNACOMTL3MBTL1 | |
| SCHEMBL2375495 | 0.76 | L3MBTL1 (0.59) | HCAR2HCAR3LMNACOMTMME | |
| SCHEMBL18803867 | 0.74 | GFER (0.41) | LMNACOMTL3MBTL1 | |
| SCHEMBL17938569 | 0.73 | HCAR2 (0.51) | HCAR2HCAR3LMNA | |
| SCHEMBL2375250 | 0.73 | LMNA (0.55) | LMNACOMTL3MBTL1CYP11B1CYP11B2 | |
| SCHEMBL14837466 | 0.72 | HCAR2 (0.52) | HCAR2HCAR3LMNA | |
| SCHEMBL11789235 | 0.70 | HCAR2 (0.48) | HCAR2HCAR3LMNAMMEL3MBTL1 | |
| SCHEMBL18010760 | 0.70 | HCAR2 (0.60) | HCAR2HCAR3COMT | |
| SCHEMBL7707048 | 0.69 | PDCD1 (0.44) | PSMB5 | |
| SCHEMBL2374361 | 0.69 | LMNA (0.58) | LMNACOMTL3MBTL1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676693-B2 | Bulky ligands and metal compounds comprising bulky ligands | MARSHAK MICHAEL PESEK (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170121263-A1 | BULKY LIGANDS AND METAL COMPOUNDS COMPRISING BULKY LIGANDS | MARSHAK MICHAEL PESEK (US) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121263-A1 | BULKY LIGANDS AND METAL COMPOUNDS COMPRISING BULKY LIGANDS | ACACB, ACACA, ZKSCAN2 | HCAR2 1969/4885HCAR3 2846/4885LMNA 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.